EraCal, a Swiss biotech developing an anti-obesity drug, aims to raise CHF 15m in a Series A round next year, according to Mergermarket who spoke with its CEO. The funds will help the company conduct GLP toxicology and Phase I studies of its lead anti-obesity asset, ERA-107. The Zurich-based company will open the round in 1Q 2021 and aims to close it by summer 2021. To notice that the company closed a CHF 6m seed round in October, with investors including Redalpine, Bernina BioInvest and the UZH Life Sciences Fund, a partnership between UZH Foundation and Novartis Venture Fund.
VISCHER is advising EraCal in this operation.